Grade 4 Events Are as Important as AIDS Events in the Era of HAART

Journal of Acquired Immune Deficiency Syndromes

Volumn 34, Issue 4, 2003, Pages 379-386

  Reisler, Ronald B ^a,f   Han, Cong ^b   Burman, William J ^c   Tedaldi, Ellen M ^d   Neaton, James D ^e  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d TEMPLE UNIVERSITY HOSPITAL   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

AIDS; Comorbidities; HAART; Morbidity; Mortality

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DEATH; DISEASE ASSOCIATION; DRUG SAFETY; EXPERIENCE; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; INCIDENCE; KIDNEY DISEASE; LIFE EVENT; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORBIDITY; MULTICENTER STUDY; NEUTROPENIA; OUTCOMES RESEARCH; PANCREATITIS; PREDICTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOCYTOPENIA; UNITED STATES;

ADULT; ANEMIA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARDIOVASCULAR DISEASES; COHORT STUDIES; FEMALE; HEPATITIS; HIV INFECTIONS; HIV-1; HUMANS; INCIDENCE; KIDNEY DISEASES; LIVER DISEASES; MALE; MENTAL DISORDERS; MULTICENTER STUDIES; MULTIVARIATE ANALYSIS; NEUTROPENIA; PANCREATITIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; UNITED STATES;

EID: 0344393509     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200312010-00004     Document Type: Article

References (82)

1. Fleming PL, Ward JW, Karon JM, et al. Declines in AIDS incidence and deaths in the USA: a signal change in the epidemic. AIDS. 1998;12(suppl A):S55-S61.
2. Detels R, Munoz A, McFarlane G, et al. Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. JAMA. 1998;280:1497-1503.
3. Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
4. Palella FJ, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Infection. N Engl J Med. 1998;338:853-860.
5. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science. 1998;280:1866-1867.
6. Carpenter CC, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA. 1997;277:1962-1969.
7. Ho DD. Time to hit HIV, early and hard. N Engl J Med. 1995;333:450-451.
8. Chun TW, Fauci AS. Latent reservoirs of HIV: obstacles to the eradication of the virus. Proc Natl Acad Sci U S A. 1999;96:10958-10961.
9. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. Rockville, MD: US Department of Health and Human Services; 2003. Available at: http://aidsinfo.nih.gov/guidelines/ Accessed July 31, 2003.
10. Yeni PG, Hammer SM, Carpenter CCJ, et al. Antiretroviral treatment for adult HIV infection in 2002: updated recommendations of the International AIDS Society: USA panel. JAMA. 2002;288:222-235.
11. Lalezari JP, Henry K, O'Heam M, et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2186-2195.
12. Sanne I, Piliero P, Squires K, et al. Results of a phase 2 clinical trial at 48 weeks (A1424-007): a dose-ranging, safety, and efficacy comparative trial of atazanavir at three doses in combination with didanosine and stavudine in antiretroviral-naive subjects. J Acquir Immune Defic Syndr. 2003;32:18-29.
13. Emtriva (emtricitabine) [package insert]. Foster City, CA: Gilead Sciences, Inc.; 2003.
14. Moses A, Nelson J, Bagby GC Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood. 1998;91:1479-1495.
15. Peruzzi M, Azzari C, Rossi ME, et al. Inhibition of natural killer cell cytotoxicity and interferon gamma production by the envelope protein of HIV and prevention by vasoactive intestinal peptide. AIDS Res Hum Retroviruses 2000;16:1067-1073.
16. Boutet A, Altmeyer R, Hery C, et al. Direct role of plasma membrane-expressed gp120/41 in toxicity to human astrocytes induced by HIV-1-infected macrophages. AIDS. 2000;14:2687-2697.
17. Ferri KF, Jacotot E, Blanco J, et al. Mitochondrial control of cell death induced by HIV-1-encoded proteins. Ann N Y Acad Sci. 2000;926:149-164.
18. Coopman SA, Johnson RA, Platt R, et al. Cutaneous disease and drug reactions in HIV infection. N Engl J Med. 1993;328:1670-1674.
19. Gates AE, Kaplan LD. AIDS malignancies in the era of highly active antiretroviral therapy. Oncology (Huntingt) 2002;16:441-451, 456, 459.20.
20. Childs EA, Lyles RH, Selnes OA, et al. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy. Neurology. 1999;52:607-613.
21. Hetherington S, Hughes AR, Mosteller M, et al. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet. 2002;359:1121-1122.
22. Mallal S, Nolan D, Witt C, et al. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet. 2002;359:727-732.
23. Freedman BI, Soucie JM, Stone SM, et al. Familial clustering of end-stage renal disease in blacks with HIV-associated nephropathy. Am J Kidney Dis. 1999;34:254-258.
24. Telenti A, Aubert V, Spertini F. Individualizing HIV Treatment - pharmacogenetics and immunogenetics. Lancet. 2002;359:722-723.
25. Phillips KA, Veenstra DL, Oren E, et al. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA. 2001;286:2270-2279.
26. Babiker AG, Peto T, Porter K, et al. Age as a determinant of survival in HIV infection. J Clin Epidemiol. 2001;54:S1, S16-S21.
27. Semba RD, Shah N, Strathdee SA, et al. High prevalence of iron deficiency and anemia among female injection drug users with and without HIV infection. J Acquir Immune Defic Syndr. 2002;29:142-144.
28. Moore RD, Forney D. Anemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2002;29:54-57.
29. Semba RD, Shah N, Klein RS, et al. Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis. 2002;34:260-266.
30. Levine AM, Berhane K, Masri-Lavine L, et al. Prevalence and correlates of anemia in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2001;26:28-35.
31. Gordeuk VR, Delanghe JR, Langlois MR, et al. Iron status and the outcome of HIV infection: an overview. J Clin Virol. 2001;20:111-115.
32. Abbott KC, Hypolite I, Welch PG, et al. Human immunodeficiency virus/acquired immunodeficiency syndrome-associated nephropathy at end-stage renal disease in the United States: patient characteristics and survival in the pre highly active antiretroviral therapy era. J Nephrol. 2001;14:377-383.
33. Gold J, Pocock N, Li Y. Bone mineral density abnormalities in patients with HIV infection. J Acquir Immune Defic Syndr. 2002;30:131-132.
34. Falusi OM, Aberg JA. HIV and cardiovascular risk factors. AIDS Read. 2001;11:263-268.
35. Kilbourne AM, Justice AC, Rabeneck L, et al. General medical and psychiatric comorbidity among HIV-infected veterans in the post-HAART era. J Clin Epidemiol. 2001;54(Suppl 1):S22-S28.
36. Dore GJ, Cooper DA. The impact of HIV therapy on co-infection with hepatitis B and hepatitis C viruses. Curr Opin Infect Dis. 2001;14:749-755.
37. Graham CS, Baden LR, Yu E, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a metaanalysis. Clin Infect Dis. 2001;33:562-569.
38. Duong M, Petit JM, Piroth L, et al. Association between insulin resistance and hepatitis C virus chronic infection in HIV-hepatitis C virus-coinfected patients undergoing antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;27:245-250.
39. den Brinker M, Wit FW, Wertheim-van Dillen PM, et al. Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS. 2000;14:2895-2902.
40. Sulkowski MS, Thomas DL, Chaisson RE, et al. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA. 2000;283:74-80.
41. Manegold C, Hannoun C, Wywiol A, et al. Reactivation of hepatitis B virus replication accompanied by acute hepatitis in patients receiving highly active antiretroviral therapy. Clin Infect Dis. 2001;32:144-148.
42. French MAH. Antiretroviral therapy immune restoration disease in HIV-infected patients on HAART. AIDS Read. 1999;9:548-562.
43. Burman WJ, Jones BE. Treatment of HIV-related tuberculosis in the era of effective antiretroviral therapy. Am J Crit Care Med. 2001;164:7-12.
44. Steketee RW, Nahlen BL, Parise ME, et al. The burden of malaria in pregnancy in malaria-endemic areas. Am J Trop Med Hyg. 2001;64:28-35.
45. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. AIDS. 2002;16:569-77.
46. Clarke SM, Mulcahy FM, Tjia J, et al. The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol. 2001;51:213-217.
47. Rainey PM. HIV drug interactions: the good, the bad, and the other. Ther Drug Monit. 2002;24:26-31.
48. Morse GD. Drug interactions with antiretrovirals. Curr Infect Dis Rep. 2000;2:257-266.
49. Ernst E. Second thoughts about safety of St John's wort. Lancet. 1999;354:1014-1015.
50. Wheeler DA, Gibert CL, Launer CA, et al. Weight loss as a predictor of survival and disease progression in HIV infection. Terry Beim Community Programs for Clinical Research on AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. 1998;18:80-85.
51. Villamor E, Msamanga G, Spiegelman D, et al. HIV status and sociodemographic correlates of maternal body size and wasting during pregnancy. Eur J Clin Nutr. 2002;56:415-424.
52. Shuter J, Chang CJ, Klein RS. Prevalence and predictive value of over-weight in an urban HIV care clinic. J Acquir Immune Defic Syndr. 2001;26:291-297.
53. Forrester JE, Woods MN, Knox TA, et al. Body composition and dietary intake in relation to drug abuse in a cohort of HIV-positive persons. J Acquir Immune Defic Syndr. 2000;25(Suppl 1):S43-S48.
54. Shor-Posner G, Campa A, Zhang G, et al. When obesity is desirable: a longitudinal study of the Miami HIV-1-infected drug abusers (MIDAS) cohort. J Acquir Immune Defic Syndr. 2000;23:81-88.
55. Melchior JC, Niyongabo T, Henzel D, et al. Malnutrition and wasting, immunodepression, and chronic inflammation as independent predictors of survival in HIV-infected patients. Nutrition. 1999;15:865-869.
56. Lucas GM, Gebo KA, Chaisson RE, et al. Longitudinal assessment of the effects of drug and alcohol abuse on HIV-1 treatment outcomes in an urban clinic. AIDS. 2002;16:767-774.
57. Flexner CW, Cargill VA, Sinclair J, et al. Alcohol use can result in enhanced drug metabolism in HIV pharmacotherapy. AlDS Patient Care STDS. 2001;15:57-58.
58. Lucas GM, Cheever LW, Chaisson RE, et al. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. J Acquir Immune Defic Syndr. 2001;27:251-259.
59. Shapiro MF, Morton SC, McCaffrey DF, et al. Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. JAMA. 1999;281:2305-2315.
60. Piketty C, Castiel P, Giral P, et al. Lack of legal income is strongly associated with an increased risk of AIDS and death in HIV-infected injecting drug users. AIDS Care. 1999;11:429-436.
61. Leserman J, Jackson ED, Petitto JM, et al. Progression to AIDS: the effects of stress, depressive symptoms, and social support. Psychosom Med. 1999;61:397-406.
62. Leserman J, Petitto JM, Golden RN, et al. Impact of stressful life events, depression, social support, coping, and cortisol on progression to AIDS. Am J Psychiatry. 2000;157:1221-1228.
63. Kitahata MM, Van Rompaey SE, Shields AW. Physician experience in the care of HIV-infected persons is associated with earlier adoption of new antiretroviral therapy. J Acquir Immune Defic Syndr. 2000;24:106-114.
64. Kitahata MM, Koepsell TD, Deyo RA, et al. Physician's experience with the acquired immunodeficiency syndrome as a factor in patient's survival. N Engl J Med. 1996;334:701-706.
65. MacArthur RD, Perez G, Walmsley S, et al. CD4+ Cell Count Is a Better Predictor of Disease Progression than HIV RNA Level in Persons with Advanced HIV Infection on Highly Active Antiretroviral Therapy. Abstract 203; CROI 8, February 4-8, 2001, Chicago, IL.
66. MacArthur RD, Chen L, Mayers DL, et al. The rationale and design of the CPCRA (Terry Beim Community Programs for Clinical Research on AIDS) 058 FIRST (Flexible Initial Retrovirus Suppressive Therapies) trial. Control Clin Trials. 2001;22:176-190.
67. El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beim Community Programs for Clinical Research on AIDS. N Engl J Med. 2000;342:1085-1092.
68. Abrams DI, Bebchuk JD, Denning ET, et al. Randomized, open-label study of the impact of two doses of subcutaneous recombinant interleukin-2 on viral burden in patients with HIV-1 infection and CD4+ cell counts of > or = 300/mm3: CPCRA 059. J Acquir Immune Defic Syndr. 2002;29:221-231.
69. Lawrence, J, Mayers D, Huppler-Hullsiek K, et al. Structured treatment interruption in patients with multidrug resistant human immunodeficiency virus. N Engl J Med. 2003;349:837-846.
70. Green LA, Price RW, Perlman DC, et al. Experience with a cross-study endpoint review committee for AIDS clinical trials. AIDS. 1998;12:1983-1990.
71. International Classification of Diseases. Ninth Revision, Clinical Modification (ICD-9-CM). Washington, DC: U.S. Dept. of Health and Human Services, Public Health Service, Health Care Financing Administration; 1988.
72. Saravolatz LD, Winslow DL, Collins G, et al. Zidovudine alone or in combination with didanosine or zalcitabine in HIV-infected patients with the acquired immunodeficiency syndrome or fewer than 200 CD4 cells per cubic millimeter. N Engl J Med. 1996;335:1099-1106.
73. Lasser KE, Allen PD, Woolhandler SJ, et al. Timing of new black box warnings and withdrawals for prescription medications. JAMA. 2002;287:2215-2220.
74. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: an evaluation of 7 medical areas. JAMA. 2001;285:437-443.
75. Edwards JE, McQuay HJ, Moore RA, et al. Reporting of adverse effects in clinical trials should be improved: lessons from acute postoperative pain. J Pain Symptom Manage. 1999;18:427-437.
76. Periard D, Telenti A, Sudre P, et al. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors. The Swiss HIV Cohort Study. Circulation. 1999;100:700-705.
77. Stein JH, Klein MA, Bellehumeur JL, et al. Use of human immunodeficiency virus-1 protease inhibitors is associated with atherogenic lipoprotein changes and endothelial dysfunction. Circulation. 2001;104:257-262.
78. Dressman J, Kincer J, Maveev SV, et al. HIV protease inhibitors promote atherosclerotic lesion formation independent of dyslipidemia by increasing CD36-dependent cholesteryl ester accumulation in macrophages. J Clin Invest. 2003;111:389-397.
79. Puzantian T. Central nervous system adverse effects with efavirenz: case report and review. Pharmacotherapy. 2002;22:930-933.
80. Welch KJ, Morse A. Association between efavirenz and selected psychiatric and neurological conditions. J Infect Dis. 2002;185:268-269.
81. United States Renal Data System 1999 Annual Data Report: part II. Incidence and prevalence of ESRD. Am J Kidney Dis. 1999;34(2 Suppl 1):S40-S50.
82. Fisher EJ, Chaloner K, Cohn DL, et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS. 2001;15:1695-1700.